PBI premier bionics limited

emphysema .... big bucks

  1. 19,875 Posts.
    lightbulb Created with Sketch. 1010
    Great announcement, three months of trials in Melbourne which should establish the unique abilities of the acoustic diagnostics ..... governments would love to screen early for this disease because the cost further down the line to treat people is huge. This is further down the line for PBI, but shows the pipeline has some blockbusters on the way. now for some news on an airways clear commercial deal.

    First Non-Invasive Chronic Obstructive Pulmonary Disease Diagnostic
    Device Commences Clinical Study
    13th May 2005: Premier Bionics Limited (ASX: PBI) today announced that its 100% owned
    subsidiary, PulmoSonix Pty Ltd, has commenced a clinical study at The Alfred Hospital in
    Melbourne to evaluate its Chronic Obstructive Pulmonary Disease (COPD) early detection
    diagnostic device.
    The PulmoScreenTM diagnostic device, based on PulmoSonix’s proprietary acoustic
    technology, aims to diagnose emphysema at an earlier presymptomatic phase of the
    disease. Currently, emphysema is diagnosed late in the course of the disease when
    symptoms are present. When the disease is at this advanced stage there are very few
    successful treatment options.
    Present methods of diagnosing emphysema are expensive and invasive. They are also not
    sensitive enough to differentiate emphysema from other forms of COPD (such as chronic
    bronchitis).
    PulmoScreenTM is designed to offer a non-invasive, rapid, low cost and definitive diagnosis of
    COPD at a stage before irreversible lung damage has occurred.
    In the case of emphysema, the aim is that PulmoScreenTM can detect the very early stages of
    the disease before clinical symptoms are detectable and at a time when lifestyle changes,
    including smoking cessation, will have a significant impact on reducing the morbidity and
    mortality associated with the disease.
    Chronic Obstructive Pulmonary Disease (COPD) is a significant public health issue. Globally,
    the cost of COPD is well in excess of $60 billion dollars annually. (In Australia COPD costs
    the community more than $500 million annually and approximately 80-90% of cases are
    attributable to smoking).
    The clinical study is led by Associate Professor Trevor Williams, Clinical Director,
    Department of Allergy, Immunology and Respiratory Medicine at The Alfred. It aims to
    provide proof of concept that the device successfully detects emphysema in a pilot study,
    planned to be completed within three months. If successful, larger scale clinical studies are
    planned together with the acceleration of discussions regarding the commercialisation of this
    device.
    The development and clinical study of the COPD early detection device is being supported
    by an AusIndustry R&D Start grant.
 
watchlist Created with Sketch. Add PBI (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.